Targeting signal transduction as a strategy to treat inflammatory diseases

Nature Reviews Drug Discovery

Volumn 5, Issue 7, 2006, Pages 549-563

  O'Neill, Luke A J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIINFLAMMATORY AGENT; BORTEZOMIB; CILOMILAST; DORAMAPIMOD; ERLOTINIB; ETANERCEPT; EVEROLIMUS; FINGOLIMOD; GEFITINIB; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NATALIZUMAB; PROSTAGLANDIN; RITUXIMAB; ROFECOXIB; ROFLUMILAST; SCIO 469; SILDENAFIL; STAT PROTEIN; TEMSIROLIMUS; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR; TRASTUZUMAB; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

ASTHMA; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CROHN DISEASE; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MANUFACTURE; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ERECTILE DYSFUNCTION; FINANCIAL MANAGEMENT; HEART DISEASE; HOST RESISTANCE; HUMAN; INFLAMMATION; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROSTAGLANDIN SYNTHESIS INHIBITION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STROKE; T LYMPHOCYTE ACTIVATION; TOOTH PAIN; TREATMENT FAILURE; TUBERCULOSIS; ULCER;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION; STEROIDS;

EID: 33745679123     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2070     Document Type: Review

References (96)

1. Olsen, N. J. & Stein, C. M. New drugs for rheumatoid arthritis. N. Engl. J. Med. 350, 2167-2179 (2004).
2. Wang, D., Wang, M., Cheng, Y. & Fitzgerald, G. A. Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curr. Opin. Pharmacol. 5, 204-210 (2005).
3. Fleischmann, R. & Yocum, D. Does safety make a difference in selecting the right TNF antagonist? Arthritis Res. Ther. 6, S12-S18 (2004).
4. Edwards, J. C. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572-2581 (2004).
5. Kremer, J. M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349, 1907-1915 (2003).
6. Sandborn, W. J. et al. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353, 1912-1925 (2005).
7. Spina, D. The potential of PDE4 inhibitors in respiratory disease. Curr. Drug Targets Inflamm. Allergy 3, 231-236 (2004).
8. Chung, K. F. Phosphodiesterase inhibitors in airways disease. Eur. J. Pharmacol. 533, 110-117 (2006).
9. Corbin, J. D. & Francis, S. H. Cyclic GMP phosphodiesterase-5: Target of sildenafil. J. Biol. Chem. 274, 13729-13732 (1999).
10. Herbst, R. S. & Kies, M. S. Gefitinib: Current and future status in cancer therapy. Clin. Adv. Hematol. Oncol. 1, 466-472 (2003).
11. Perez-Soler, R. et al. Final results from a Phase II study of erlotinib monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy. Lung Cancer 41, S246 (2003).
12. Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
13. Druker, B. J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukaemia and acute lymphoblastic leukaemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042 (2001).
14. Miossec, P. The role of interleukin 1 in the pathogenesis of rheumatoid arthritis. Clin. Exp. Rheumatol. 5, 305-308 (1987).
15. Brennan, F. M., Maini, R. N. & Feldmann, M. TNF-α - A pivotal role in rheumatoid arthritis? Br. J. Rheumatol. 31, 293-298 (1992).
16. Gay, N. J. & Keith, F. J. Drosophila Toll and IL-1 receptor. Nature 351, 355-356 (1991).
17. O'Neill, L. A. & Greene, C. Signal transduction pathways activated by the IL-1 receptor family: Ancient signaling machinery in mammals, insects, and plants. J. Leukoc. Biol. 63, 650-657 (1998).
18. O'Neill, L. A. Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr. Opin. Pharmacol. 3, 3396-3403 (2003).
19. Sen, R. & Baltimore, D. Inducibility of κ-immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism. Cell 47, 921-928 (1986).
20. Osborn, L., Kunkel, S. & Nabel, G. J. Tumor necrosis factor-α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc. Natl Acad. Sci. USA 86, 2336-2340 (1989).
21. O'Neill, L. A. How Toll-like receptors signal: What we know and what we don't know. Curr. Opin. Immunol. 18, 3-9 (2006).
22. Martinon, F. & Tschopp, J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol. 26, 447-454 (2005).
23. Kolls, J. K. & Linden, A. Interleukin-17 family members and inflammation. Immunity 21, 467-476 (2004).
24. Siebenlist, U., Brown, K. & Claudio, E. Control of lymphocyte development by nuclear factor-κB. Nature Rev. Immunol. 5, 435-445 (2005).
25. Moynagh, P. N. The NF-κB pathway. J. Cell Sci. 118, 4589-4592 (2005).
26. Bonnizzi, G. et al. Activation of IKKα target genes depends on recognition of specific κB binding sites by RelB:p52 dimers. EMBO J. 23, 4202-4210 (2004).
27. Karin, M., Yamamoto, Y. & May Wang, Q. The IKK NF-κB system: A treasure trove for drug development. Nature Rev. Drug Discov. 3, 17-26 (2004).
28. di Meglio, P., Ianaro, A. & Ghosh, S. Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-κB activation. Arthritis Rheum. 52, 951-958 (2005).
29. Luo, J. L., Kamata, H. & Karin, M. IKK/NF-κB signaling: Balancing life and death - a new approach to cancer therapy. J. Clin. Invest. 115, 2625-2632 (2005).
30. Spano, J. P., Bay, J. O., Blay, J. Y. & Rixe, O. Proteasome inhibition: a new approach for the treatment of malignancies. Bull. Cancer 92, E61-E6, 945-952 (2005).
31. Proteolix, Inc. Proteolix Programs [online], (2006).
32. Han, J., Lee, J. D., Bibbs, L. & Ulevitch, R. J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265, 808-811 (1994).
33. Freshney, N. W. et al. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 78, 1039-1049 (1994).
34. Lee, J. C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739-746 (1994).
35. Kracht, M. & Saklatvala, J. Transcriptional and post-transcriptional control of gene expression in inflammation. Cytokine 20, 91-106 (2002).
36. Shim, J. H. et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 19, 2668-2681 (2005).
37. Dean, J. L., Sully, G., Clark, A. R. & Saklatvala, J. The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal. 16, 1113-1121 (2004).
38. Dominguez, C., Powers, D. A. & Tamayo, N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr. Opin. Drug Discov. Devel. 8, 421-430 (2005).
39. Goldstein, D. M. & Gabriel, T. Pathway to the clinic: Inhibition of p38 MAP kinase. A review of ten chemotypes selected for development. Curr. Top. Med. Chem. 5, 1017-1029 (2005).
40. Vertex, Inc. Vertex reports investigational p38 MAP kinase inhibitor, VX-702, meets primary objectives in Phase II clinical study in rheumatoid arthritis [online], (2006).
41. Waetzig, V. & Herdegen, T. Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. Trends Pharmacol. Sci. 26, 455-461 (2005).
42. Manning, A. M. & Davis, R. J. Targeting JNK for therapeutic benefit: from junk to gold. Nature Rev. Drug Discov. 2, 554-565 (2003).
43. Eynott, P. R., Adcock, I. M. & Chung, P. The effects of a selective c-Jun N-terminal kinase inhibition in a sensitized Brown Norway rat model of allergic asthma. Am. J. Respir. Crit. Care Med. 49, S102 (2001).
44. Han, Z. et al. Jun-N-terminal kinase in rheumatoid arthritis. J. Pharm. Exp. Ther. 291, 124-130 (1999).
45. Kassel, O. et al. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J. 20, 7108-7116 (2001).
46. Lasa, M., Abraham, S. M., Boucheron, C., Saklatvala, J. & Clark, A. R. Dexamethasone causes sustained expression of MKP-1 and phosphatase-mediated inhibition of MAPK p38. Mol. Cell. Biol. 22, 7802-7811 (2002).
47. O'Shea, J. J., Pesu, M., Borie, D. C. & Changelian, P. S. A new modality for immunosuppression: Targeting the JAK/STAT pathway. Nature Rev. Drug Discov. 3, 555-564 (2004).
48. Changelian, P. S. et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875-878 (2003).
49. Baslund, B. et al. Targeting interleukin-15 in patients with rheumatoid arthritis: A proof-of-concept study. Arthritis Rheum. 52, 2686-2692 (2005).
50. Bissonnette, R. et al. A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol. 54, 472-478 (2006).
51. Chiba, K., Matsuyuki, H., Maeda, Y. & Sugahara, K. Role of sphingosine 1-phosphate receptor type I in lymphocyte egress from secondary lymphoid tissues and thymus. Cell. Mol. Immunol. 3, 11-19 (2006).
52. Fujino, M. et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. 305, 70-77 (2003).
53. Medical News Today. Multiple sclerosis - FTY720, a novel once-daily oral medication, shows promising results [online], (2005).
54. Young, D. A. & Nickerson-Nutter, C. L. mTOR - beyond transplantation. Curr. Opin. Pharmacol. 5, 418-423 (2005).
55. Ghosh, P., Buchholz, M. A., Yano, S., Taub, D. & Longo, D. L. Effect of rapamycin on the cyclosporine-resistant CD28-mediated costimulatory pathway. Blood 99, 4517-4524 (2002).
56. Mayer, D. F. & Kushwaha, S. S. Transplant immunosuppressant agents and their role in autoimmune rheumatic diseases. Curr. Opin. Rheumatol. 15, 219-225 (2003).
57. Lehle, K., Birnbaum, D. E. & Preuner, J. G. Predominant inhibition of interleukin-6 synthesis in patient-specific endothelial cells by mTOR inhibitors below a concentration range where cell proliferation is affected and mitotic arrest takes place. Transplant Proc. 37, 159-161 (2005).
58. Dancey, J. E. Inhibitors of the mammalian target of rapamycin. Expert Opin. Investig. Drugs 14, 313-328 (2005).
59. Moseley, T. A., Haudenschild, D. R., Rose, L. & Reddi, A. H. Interleukin-17 and IL-17 receptors. Cytokine Growth Factor Rev. 14, 155-174 (2003).
60. Lubberts, E. The role of IL-17 and family members in the pathogenesis of arthritis. Curr. Opin. Investig. Drugs 4, 572-577 (2003).
61. Hee, M. M. et al. Small-molecule inhibition of TNF-α Science 11, 1022-1025 (2005).
62. Bouwmeester, T. et al. A physical and functional map of the human TNF/ NF-κB signal transduction pathway. Nature Cell Biol. 6, 97-105 (2004).
63. Janssens, S. & Beyaert, R. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol. Cell 11, 293-302 (2003).
64. O'Neill, L. A., Fitzgerald, K. A. & Bowie, A. G. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol. 24, 286-290 (2003).
65. Fitzgerald, K. A. et al. IKKε and TBK1 are essential components of the IRF3 signaling pathway. Nature Immunol. 4, 491-496 (2003).
66. Sharma, S. et al. Triggering the interferon antiviral response through an IKK-related pathway. Science 300, 1148-1151 (2003).
67. Hacker, H. et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439, 204-207 (2006).
68. Oganesyan, G. Critical role of TRAF3 in the Toll-like receptor-dependent and-independent antiviral response. Nature 439, 208-211 (2006).
69. Honda, K. et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434, 1035-1040 (2005).
70. Uematsu, S. et al. IRAK-1 plays an essential role for TLR7- and TLR9-mediated interferon-α induction. J. Exp. Med. 201, 915-923 (2005).
71. Siebl, R. et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am. J. Pathol. 162, 1221-1227 (2003).
72. Leadbetter, E. A. et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416, 603-607 (2002).
73. Lau, C. M. et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202, 1171-1177 (2005).
74. Bartfai, T. et al. A low molecular weight mimic of Toll/IL-1 receptor/ resistance domain inhibits IL-1 receptor-mediated responses. Proc. Natl Acad. Sci. USA 100, 7971-7976 (2003).
75. Harte, M. et al. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defence. J. Exp. Med. 197, 343-351 (2003).
76. McCoy, S. L., Kurtz, S. E., MacArthur, C. J., Trune, D. R. & Hefeneider, S. H. Identification of a peptide derived from Vaccinia virus A52R protein that inhibits cytokine secretion in response to TLR-dependent signalling and reduces in vivo bacterial-induced inflammation. J. Immunol. 174, 3006-3014 (2005).
77. Holtmann, M. M. RDP-58 (Sangstat medical). IDrugs 6, 1188-1194 (2003).
78. Travis, S. et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm. Bowel Dis. 11, 713-719 (2005).
79. Ogura, Y. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603-606 (2001).
80. Hugot, J. P. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599-603 (2001).
81. Strober, W., Murray, P. J., Kitani, A. & Watanabe, T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nature Rev. Immunol. 6, 9-20 (2006).
82. Watanabe, T., Kitani, A., Murray, P. J. & Strober, W. NOD2 is a negative regulator of TLR-2-mediated T helper Type I responses. Nature Immunol. 5, 800-808 (2004).
83. Maeda, S. et al. Nod2 mutation in Crohn's disease potentiates NF-κB activity and IL-1β processing. Science 307, 734-738 (2005).
84. Mariathasan, S. et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228-232 (2006).
85. Kanniganti, T. D. et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440, 233-236 (2006).
86. Siegmund, B. & Zeitz, M. Pralnacasan (Vertex pharmaceuticals). IDrugs 6, 154-158 (2003).
87. Agostini, L. et al. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20, 319-325 (2004).
88. Dinarello, C. A. Unravelling the NALP3/IL-1β inflammasome: A big lesson from a small mutation. Immunity 20, 243-246 (2004).
89. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006).
90. Ogawa, S. et al. Molecular determinants of crosstalk between nuclear receptors and Toll-like receptors. Cell 122, 707-721 (2005).
91. Wietek, C., Miggin, S. M., Jefferies, C. A. & O'Neill, L. A. Interferon regulatory factor-3-mediated activation of the interferon-sensitive response element by Toll-like receptor (TLR) 4 but not TLR3 requires the p65 subunit of NF-κ. J. Biol. Chem. 278, 50923-50931 (2003).
92. Humbert, M. Ciclesonide: A novel inhaled corticosteroid. Expert Opin. Investig. Drugs 13, 1349-1360 (2005).
93. Belvisi, M. G. et al. Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma. J. Pharmacol. Exp. Ther. 314, 568-574 (2005).
94. Lee, K. S. PPAR-γ modulates allergic inflammation through up-regulation of PTEN. FASEB J. 19, 1033-1035 (2005).
95. Belvisi, M. G., Hele, D. J. & Birrell, M. A. New advances and potential therapies for the treatment of asthma. BioDrugs 18, 211-223 (2004).
96. Staels, B. et al. Activation of human aortic smooth-muscle cells is inhibited by PPAR-α but not PPAR-γ activators. Nature 393, 790-793 (1998).